Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Hennrich, Ute; Kopka, Klaus

doi:10.3390/ph12030114

Open AccessReview

Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

by

Ute Hennrich

^1,*

and

Klaus Kopka

^1,2

¹

German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

²

German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

^*

Author to whom correspondence should be addressed.

Pharmaceuticals 2019, 12(3), 114; https://doi.org/10.3390/ph12030114

Submission received: 1 July 2019 / Revised: 23 July 2019 / Accepted: 26 July 2019 / Published: 29 July 2019

(This article belongs to the Special Issue The Story of Successful Drugs and Recent FDA-Approved Molecules)

Download

Browse Figures

Versions Notes

Abstract

As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera^® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera^® combines the radionuclide ¹⁷⁷Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors. As a result, DNA single- and double-strand breaks are provoked, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions.

Keywords: Lutathera^®, [¹⁷⁷Lu]Lu-DOTA-TATE; thera(g)nostics; peptide receptor radionuclide therapy (PRRT); somatostatin receptor (SSTR); neuroendocrine tumors (NET)

Share and Cite

MDPI and ACS Style

Hennrich, U.; Kopka, K. Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals 2019, 12, 114. https://doi.org/10.3390/ph12030114

AMA Style

Hennrich U, Kopka K. Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals. 2019; 12(3):114. https://doi.org/10.3390/ph12030114

Chicago/Turabian Style

Hennrich, Ute, and Klaus Kopka. 2019. "Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy" Pharmaceuticals 12, no. 3: 114. https://doi.org/10.3390/ph12030114

APA Style

Hennrich, U., & Kopka, K. (2019). Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals, 12(3), 114. https://doi.org/10.3390/ph12030114

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI